股票代码：002391 股票简称：长青股份 公告编号：2025-012 江苏长青农化股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 公司于2025年4月16日召开第九届董事会第二次会议，审议通过了《关于为 全资子公司提供担保的议案》，为推进全资子公司长青（湖北）生物科技有限公 司（以下简称"长青湖北"）项目建设，同意长青湖北向银行等金融机构申请不 超过人民币8,800万元固定资产项目贷款，借款期限为5年，公司在上述贷款额度 和期限内为长青湖北提供全额连带责任保证担保。 根据《深圳证券交易所股票上市规则》和《公司章程》的相关规定，上述担 保事项在公司董事会审批权限之内，无需提交公司股东大会审议。 二、被担保人基本情况 1、基本情况 被担保人名称：长青（湖北）生物科技有限公司 成立日期：2019年7月17日 住所：湖北省宜昌姚家港化工园田家河片区马家铺路6号 法定代表人：张琳 注册资本：80,000万元 公司类型：有限责任公司（非自然人投资或控股的法人独资） 经营范围：许可项目:农药生产,农药批发,有 ...

根据《上市公司监管指引第10号—市值管理》的相关规定，股票连续12个月 每个交易日收盘价均低于其最近一个会计年度经审计的每股归属于公司普通股 股东的净资产的上市公司，应当制定上市公司估值提升计划，并经董事会审议后 披露。 江苏长青农化股份有限公司（以下简称公司）于2024年4月18日披露了《2023 年年度报告》，2024年1月1日至2024年4月18日每日收盘价均低于2022年经审计 每股净资产（7.14元），2024年4月19日至2024年12月31日每日收盘价均低于2023 年经审计每股净资产（7.05元），长青股份股票已连续12个月每个交易日收盘价 均低于最近一个会计年度经审计的每股归属于上市公司股东的净资产，属于应当 制定估值提升计划的情形。 股票代码：002391 股票简称：长青股份 公告编号：2025-013 江苏长青农化股份有限公司 2025 年度估值提升计划 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、触及情形及审议程序 （一）触发情形 （二）审议程序 2025年4月16日，公司召开第九届董事会第二次会议，会议审议通过了公司 《202 ...

江苏长青农化股份有限公司 2024 年度监事会工作报告 2024年，江苏长青农化股份有限公司监事会依照《公司法》、《公司章程》 等法律法规有关规定，认真履行监督职责，积极维护全体股东的权益。 一、监事会会议召开情况： 2024年度公司监事会共召开了六次会议，召开的情况如下： 1、2024年1月31日召开了第八届监事会第九次会议，审议通过了以下议案： （1）《关于继续由全资子公司为公司贷款提供担保的议案》； 2、2024年4月16日召开第八届监事会第十次会议，审议通过了以下议案： （1）《2023年度监事会工作报告》； （2）《2023年年度报告及其摘要》； （3）《2023年度财务决算报告》； （4）《2023年度利润分配预案》； （5）《2023年度内部控制自我评价报告》； （6）《2023年度募集资金存放与使用情况的专项报告》； （7）《2024年第一季度报告》； （8）《关于继续使用暂时闲置募集资金进行现金管理的议案》； （9）《关于续聘会计师事务所的议案》； （10）《未来三年（2024-2026年）股东回报规划》。 3、2024年8月20日召开第八届监事会第十一次会议，审议通过了以下议案： （1）《 ...

江苏长青农化股份有限公司 2024年度募集资金存放与使用情况专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以 及《深圳证券交易所上市公司自律监管指南第 2 号——公告格式》的相关规定， 本公司就 2024 年度募集资金存放与使用情况作如下专项报告： 一、 募集资金基本情况 经中国证券监督管理委员会《关于核准江苏长青农化股份有限公司公开发行 可转换公司债券的批复》（证监许可[2018]2097 号）核准，公司于 2019 年 2 月 27 日向社会公开发行 913.8 万张可转换公司债券，每张面值 100 元，公开发行可 转债募集资金总额为 913,800,000.00 元，扣除承销费、保荐费等发行费用 21,047,380.00 元后，本次募集资金净额为 892,752,620.00 元。募集资金到位情况 业经立信会计师事务所（特殊普通合伙）验证，并 2019 年 3 月 5 日出具了信会 师报字[2019]第 ZH10 ...

股票代码：002391 股票简称：长青股份 公告编号：2025-014 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏长青农化股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开 第九届董事会第二次会议，审议通过了《关于召开 2024 年年度股东大会的议案》， 会议决定于 2025 年 5 月 8 日召开 2024 年年度股东大会。现就关于召开 2024 年 年度股东大会的事项公告如下： 一、召开会议的基本情况 1、股东大会届次：公司 2024 年年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会会议召开符合《公司法》、《证 券法》、《深圳证券交易所股票上市规则》、《公司章程》等有关规定。 4、会议召开的日期、时间： 江苏长青农化股份有限公司 7、会议召开方式：采用现场会议与网络投票相结合的方式 （1）现场投票：包括本人出席及通过填写授权委托书委托他人出席； （ 2 ） 网 络 投 票 ： 公 司 将 通 过 深 圳 证 券 交 易 所 系 统 和 互 联 网 系 ...

股票代码：002391 股票简称：长青股份 公告编号：2025-005 江苏长青农化股份有限公司 第九届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载，误导性陈述或重大遗漏。 江苏长青农化股份有限公司（以下简称"公司"）第九届监事会第二次会议于 2025 年 4 月 16 日在公司会议室以现场方式召开，会议通知于 2025 年 3 月 25 日 以通讯方式发送至公司全体监事。会议由监事会主席于国庆先生主持，会议应到 监事 3 人，实到监事 3 人。本次会议的召集、召开程序及出席会议的监事人数符 合《公司法》和《公司章程》的规定。 经与会监事认真审议，本次会议以记名投票表决方式通过了以下决议： 一、审议通过了《2024 年度监事会工作报告》 二、审议通过了《2024 年年度报告及其摘要》 经审核，监事会认为：董事会编制和审核《2024 年年度报告及其摘要》的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2024 年年度报告》全文刊登于 2025 年 4 月 18 日 ...

经与会董事认真审议，本次会议以记名投票表决方式通过了以下决议： 一、审议通过了《2024 年度董事会工作报告》 2024 年，公司董事会严格按照法律法规、规范性文件及《公司章程》的规 定，本着对全体股东负责的态度，贯彻落实股东大会各项决议，全体董事恪尽职 守、勤勉尽职。 公司现任独立董事骆广生先生、杨光亮先生、石柱先生，任期届满离任独立 董事龚新海先生、李钟华女士已向公司董事会提交了《2024 年度述职报告》，现 任独立董事将在公司 2024 年年度股东大会上述职。 《2024 年度董事会工作报告》、独立董事《2024 年度述职报告》全文刊登于 2025 年 4 月 18 日的巨潮资讯网。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 股票代码：002391 股票简称：长青股份 公告编号：2025-004 江苏长青农化股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏长青农化股份有限公司（以下简称"公司"）第九届董事会第二次会议 于 2025 年 4 月 16 日在公司会议室以现场方式召开，会议通知于 2 ...

Financial Performance - The company's revenue for Q1 2025 was ¥920,048,502.11, representing a 7.00% increase compared to ¥859,885,614.78 in the same period last year[5]. - Net profit attributable to shareholders increased by 111.17% to ¥16,689,700.90 from ¥7,903,609.81 year-on-year[5]. - The net profit after deducting non-recurring gains and losses rose by 77.77% to ¥18,217,239.58 compared to ¥10,247,850.41 in the previous year[5]. - Total operating revenue for the current period reached ¥920,048,502.11, an increase of 7.0% compared to ¥859,885,614.78 in the previous period[17]. - Net profit for the current period was ¥16,689,700.90, representing a significant increase of 111.5% from ¥7,902,233.59 in the previous period[18]. - Operating profit rose to ¥22,023,995.98, a 92.6% increase compared to ¥11,440,761.95 in the last period[18]. - The total comprehensive income for the current period was ¥16,720,300.90, compared to ¥6,203,933.59 in the previous period[18]. Assets and Liabilities - The company's total assets increased by 9.10% to ¥9,427,055,024.32 from ¥8,640,792,209.03 at the end of the previous year[5]. - Total current assets increased to CNY 3,730,890,490.70 from CNY 2,974,160,771.71, representing a growth of approximately 25.4%[13]. - Total assets reached CNY 9,427,055,024.32, up from CNY 8,640,792,209.03, indicating a growth of approximately 9.1%[15]. - Total liabilities increased to CNY 5,200,646,788.41 from CNY 4,412,298,351.51, reflecting a rise of about 17.8%[15]. - The company's total equity stands at CNY 4,226,408,235.91, slightly down from CNY 4,228,493,857.52[15]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥234,075,191.91, worsening by 72.92% compared to a net outflow of ¥135,368,776.32 in the previous year[5]. - Cash flow from operating activities showed a net outflow of ¥234,075,191.91, worsening from a net outflow of ¥135,368,776.32 in the previous period[19]. - Cash flow from investing activities resulted in a net outflow of ¥558,638,193.54, compared to a net outflow of ¥248,532,104.31 in the prior period[20]. - Cash flow from financing activities generated a net inflow of ¥897,244,591.99, an increase from ¥384,620,801.97 in the previous period[20]. - The company received cash from investment recoveries totaling ¥1,171,800,000.00, significantly higher than ¥270,000,000.00 in the last period[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,477[11]. - The largest shareholder, Yu Guoquan, holds 25.40% of the shares, amounting to 165,013,503 shares[11]. - The company has no preferred shareholders or significant changes in the top ten shareholders participating in margin trading[12]. Other Financial Metrics - The weighted average return on equity was 0.40%, up from 0.17% in the same period last year[5]. - Basic and diluted earnings per share for the current period were both ¥0.0267, up from ¥0.0122 in the previous period[18]. - The company's cash and cash equivalents increased by 41.60% to ¥368,155,896.39 from ¥259,997,453.34 at the beginning of the period[9]. - Cash and cash equivalents rose to CNY 368,155,896.39 from CNY 259,997,453.34, an increase of about 41.6%[13]. - Trade receivables rose by 46.40% to ¥1,008,284,067.05 from ¥688,727,789.85, indicating an increase in credit sales[9]. - The company reported a significant increase in government subsidies recognized as other income, which rose by 148.39% to ¥2,352,968.78 from ¥947,272.76[9]. - Short-term borrowings increased by 43.05% to ¥2,069,556,337.10 from ¥1,446,748,831.60, reflecting a rise in working capital loans[9]. - The long-term investments in fixed assets increased to CNY 3,855,103,662.07 from CNY 3,289,999,624.63, a growth of approximately 17.1%[14]. - The company reported a significant increase in accounts receivable, which rose to CNY 1,008,284,067.05 from CNY 688,727,789.85, an increase of about 46.5%[13].

Financial Performance - The company's operating revenue for 2024 was CNY 3,524,360,122.59, a decrease of 2.49% compared to CNY 3,614,477,683.62 in 2023[21] - The net profit attributable to shareholders for 2024 was a loss of CNY 119,953,643.52, representing a decline of 264.06% from a profit of CNY 73,113,919.75 in 2023[21] - The basic earnings per share for 2024 was CNY -0.1882, a decline of 267.14% compared to CNY 0.1126 in 2023[21] - The net profit attributable to shareholders was CNY -119.95 million, a year-on-year decline of 264.06%[65] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -125.33 million, a year-on-year decrease of 246.08%[65] - The gross profit margin for the pesticide segment was 8.38%, reflecting a decrease of 5.76% year-on-year[69] Cash Flow and Assets - The net cash flow from operating activities improved significantly to CNY 317,958,732.39, a 444.56% increase from a negative cash flow of CNY 92,280,094.03 in 2023[21] - The company's total assets at the end of 2024 increased by 7.33% to CNY 8,640,792,209.03 from CNY 8,050,482,608.58 in 2023[21] - The net assets attributable to shareholders decreased by 7.65% to CNY 4,228,493,857.52 from CNY 4,578,569,633.45 in 2023[21] - The net cash flow from operating activities increased by 444.56% year-on-year, primarily due to reduced cash payments for goods and services as a result of the relocation of the Jiangsu plant[83] Market and Industry Trends - The global pesticide market has grown from $35.57 billion in 2006 to $87.7 billion in 2022, with a compound annual growth rate of approximately 5.80%[31] - China accounts for over 50% of the global pesticide production, indicating a strong position in the global market[32] - The industry is undergoing consolidation towards larger, more efficient operations, driven by increased competition and environmental pressures[33] - The company is focusing on the development of new environmentally friendly pesticides, which are expected to grow rapidly due to stricter regulations on traditional pesticides[34] Production and Capacity - The production capacity for the main product, raw medicine, is 43,910 tons/year, with a utilization rate of 60.82%[47] - The production capacity for the formulation is 20,000 tons/year, with a utilization rate of 88.42%[47] - The company has an annual production capacity of 6,400 tons for Fluazifop-P-butyl, positioning it as a leading producer and exporter in the domestic market[50] - The production capacity for Imidacloprid is 3,000 tons per year, with approximately 50% allocated for export, achieving full production and sales[51] - The company has successfully created 30 new pesticide varieties with independent intellectual property rights, achieving a cumulative promotion area of over 300 million mu, with some products exceeding sales of 200 million yuan[35] Research and Development - The company has a strong R&D team and has undertaken multiple national and provincial-level research projects[55] - The company emphasizes the development of high-efficiency, low-toxicity, and low-residue pesticides as a key focus for future R&D[108] - The company has established partnerships with numerous research institutions for technological innovation and product development[55] Environmental Compliance - The company has implemented a comprehensive environmental management system, achieving ISO 14001 certification[58] - The company adheres to environmental protection laws and standards, including the surface water quality standard GB3838-2002 for the Yangtze River section[163] - The company executes wastewater discharge standards, including the COD limit of ≤350 mg/L as per local regulations[163] - The company has established various environmental management systems and emergency response plans to ensure compliance with national regulations and industry standards[174] Governance and Management - The company has implemented a governance structure that includes a board of directors with independent members to enhance decision-making efficiency and risk management[122] - The company has established a comprehensive performance evaluation system and compensation scheme for senior management, linking their income directly to work performance[138] - The company has maintained communication with independent directors through various channels to monitor operational and financial conditions[144] Shareholder Relations - The company plans to distribute cash dividends of RMB 2 per 10 shares (including tax) to all shareholders, with the distribution completed by June 2024[151] - The company distributed cash dividends of 127.32 million yuan in June 2024, representing 20% of the distributable profits for the year, in line with its shareholder return plan[185] - The company commits to distributing at least 20% of its distributable profits as cash dividends annually over the next three years, contingent on profitability and no major investment plans[194] Risk Management - The company acknowledges risks related to industry competition, capacity expansion, raw material price fluctuations, and environmental policies[4] - The company has established risk management strategies to mitigate operational, safety, environmental, and financial risks[155] - The company faces significant risks including price competition, with the agricultural pesticide market being characterized by low concentration and intense price competition[113] Social Responsibility - The company engaged in social responsibility by participating in charitable activities, with total donations amounting to 8.8569 million yuan in 2024[188] - The company has conducted annual emergency response drills for environmental incidents, ensuring preparedness for potential environmental emergencies[179]

股票代码：002391 股票简称：长青股份 公告编号：2025-008 江苏长青农化股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏长青农化股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开 第九届董事会第二次会议和第九届监事会第二次会议，审议通过了《2024 年度 利润分配预案》，公司拟定 2024 年度利润分配预案为：2024 年度不派发现金红 利，不送红股，不以资本公积金转增股本，该议案尚需提交公司 2024 年度股东 大会审议，现将有关事项公告如下： 一、审议程序 （一）董事会对议案审议和表决情况 2025年4月16日，公司第九届董事会第二次会议审议通过了《2024年度利润 分配预案》，并同意将本议案提交公司2024年度股东大会审议。 （二）监事会对议案审议和表决情况 2025年4月16日，公司第九届监事会第二次会议审议通过了《2024年度利润 分配预案》，经核查，鉴于公司2024年度未实现盈利，同意2024年度利润分配预 案。该利润分配预案符合中国证监会《上市公司监 ...